Diabetes Care Devices

Global Diabetes Care Devices Market to Reach US$86.9 Billion by 2030

The global market for Diabetes Care Devices estimated at US$48.2 Billion in the year 2024, is expected to reach US$86.9 Billion by 2030, growing at a CAGR of 10.3% over the analysis period 2024-2030. Blood Glucose Monitoring Devices, one of the segments analyzed in the report, is expected to record a 12.5% CAGR and reach US$51.1 Billion by the end of the analysis period. Growth in the Insulin Delivery Devices segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.1 Billion While China is Forecast to Grow at 14.4% CAGR

The Diabetes Care Devices market in the U.S. is estimated at US$13.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$18.2 Billion by the year 2030 trailing a CAGR of 14.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 9.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global Diabetes Care Devices Market – Key Trends & Drivers Summarized

How Are Advancements in Diabetes Care Devices Enhancing Patient Outcomes?

The diabetes care devices market is undergoing a revolutionary shift, driven by technological innovations that are improving disease monitoring, management, and treatment adherence. The development of continuous glucose monitoring (CGM) systems has been a game-changer, providing real-time insights into blood sugar fluctuations and reducing dependence on traditional fingerstick testing. Additionally, insulin delivery systems, such as smart insulin pens and closed-loop insulin pumps, are making diabetes management more precise and convenient. The rise of digital health integration has further enhanced remote monitoring capabilities, allowing healthcare providers to personalize treatment plans based on real-time data. Moreover, the increasing prevalence of diabetes worldwide, particularly in developing regions, has spurred the demand for affordable and user-friendly diabetes care devices. Companies are now focusing on miniaturization and non-invasive technologies to make devices more accessible and less cumbersome for patients.

What Are the Breakthrough Innovations Transforming Diabetes Management?

The latest wave of innovations in diabetes care devices is centered around automation, AI-driven analytics, and non-invasive monitoring. Artificial pancreas systems, which automatically adjust insulin delivery based on continuous glucose readings, are revolutionizing diabetes control. Wearable and implantable sensors are emerging as promising alternatives to traditional CGMs, offering improved accuracy and longer wear durations. Smart patches with microneedle technology are also gaining traction for pain-free glucose monitoring. Another key development is the integration of AI-driven predictive analytics, which helps detect patterns and anticipate glucose fluctuations before they occur. Additionally, advances in biosensor technology are paving the way for glucose monitoring through sweat and tears, eliminating the need for invasive blood sampling. With these innovations, diabetes management is becoming more efficient and less intrusive for patients.

How Is Digital Health Reshaping the Diabetes Care Ecosystem?

The integration of digital health solutions, including mobile apps, cloud-based platforms, and telemedicine, is revolutionizing diabetes management. Smartphone-connected glucose monitors allow users to track their readings, receive real-time alerts, and share data with healthcare providers seamlessly. The proliferation of AI-driven diabetes coaching apps is also empowering patients with personalized dietary and lifestyle recommendations. The rise of remote patient monitoring programs has further strengthened chronic disease management, especially in underserved regions where access to endocrinologists is limited. Insurance companies and employers are also increasingly adopting diabetes management programs that integrate digital tools to promote proactive care. These developments are significantly enhancing patient engagement and long-term disease control.

What Are the Key Drivers Behind the Expansion of the Diabetes Care Devices Market?

The growth in the diabetes care devices market is driven by several factors, including rising diabetes prevalence, growing demand for minimally invasive monitoring solutions, and increasing adoption of digital health technologies. The expansion of artificial pancreas systems and advanced insulin delivery devices is significantly improving patient outcomes, fueling market growth. Additionally, continuous innovations in biosensor technology are making glucose monitoring more accurate and user-friendly. The increasing penetration of AI in diabetes management is also playing a pivotal role in predicting and preventing complications. Moreover, government initiatives to promote diabetes awareness and improve access to care are further accelerating market expansion. The rapid uptake of wearable health technologies and telehealth solutions is enhancing disease monitoring and treatment adherence, propelling further growth. With the ongoing technological advancements and growing patient-centric approaches, the diabetes care devices market is expected to witness sustained expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Diabetes Care Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Blood Glucose Monitoring Devices, Insulin Delivery Devices); End-Use (Hospital End-Use, Ambulatory Surgical Centers End-Use, Diagnostic Centers End-Use, Homecare End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• ACON Laboratories, Inc.
• ARKRAY, Inc.
• Ascensia Diabetes Care Holdings AG
• DarioHealth Corp.
• Dexcom, Inc.
• Diabeloop SA
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Glenmark Pharmaceuticals Ltd.
• GlucoMe
• iHealth Labs, Inc.
• Integrated Diabetes Services, LLC
• Medtronic Plc
• Novo Nordisk A/S
• Prodigy Diabetes Care, LLC
• Tandem Diabetes Care, Inc.
• Trividia Health, Inc.
• Ypsomed AG

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.